AMRX PDUFA decision: a negative outcome, -10.1%

On November 26, 2019, Amneal Pharmaceuticals, Inc. reached its PDUFA decision. The result was a negative outcome, and the stock moved -10.1% in the window around the event. It had already run -8.8% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.